You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ph 1/2

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stomach Tumor Trial (Trastuzumab deruxtecan, Afatinib)

Not yet recruiting
  • Stomach Neoplasm
  • (no location specified)
Oct 16, 2023

Heart Failure, Pulmonary Hypertension Trial in Vancouver, Ottawa (Rivet Shunt)

Not yet recruiting
  • Heart Failure
  • Pulmonary Hypertension
  • Rivet Shunt
  • Vancouver, British Columbia, Canada
  • +1 more
Sep 26, 2022

Phosphorus Metabolism Disorders, Acid-Base Balance Disorder Trial in Warsaw (Group 1: B) Dbic 35 -30 mmol/L C) Dbic 30- 35

Completed
  • Phosphorus Metabolism Disorders
  • Acid-Base Balance Disorder
  • Group 1: B) Dbic 35 -30 mmol/L C) Dbic 30- 35 mmol/L
  • Group 2: C) Dbic 30 -35 mmol/L B) Dbic 35- 30 mmol/L
  • Warsaw, Poland
    Wieliczko Monika
May 21, 2023

Hypertension, Pulmonary Trial in Germany, United Kingdom (Blood Sample, Cardiac MRI)

Completed
  • Hypertension, Pulmonary
  • Blood Sample
  • Cardiac MRI
  • Bonn, Germany
  • +7 more
Aug 16, 2022

Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma Trial in Rochester (VSV-IFNß-NIS, Pembrolizumab)

Recruiting
  • Solid Tumor
  • +2 more
  • VSV-IFNβ-NIS
  • Pembrolizumab
  • Rochester, Minnesota
    Mayo Clinic
Sep 26, 2022

COVID-19 Trial in United States (VXA-CoV2-1.1-S, Placebo Tablets)

Recruiting
  • COVID-19
  • Long Beach, California
  • +3 more
Sep 19, 2022

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811;SHR-1701;capecitabine;oxaliplatin)

Not yet recruiting
  • HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
  • (no location specified)
Jan 3, 2023

Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases Trial in Worldwide (DCR-PHXC)

Enrolling by invitation
  • Primary Hyperoxaluria Type 1 (PH1)
  • +5 more
  • San Francisco, California
  • +19 more
Jun 22, 2022

Relapsed or Refractory Multiple Myeloma Trial in Australia, China (EMB-06)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • EMB-06
  • Buderim, Queensland, Australia
  • +5 more
May 4, 2022

Anastomotic Leak Trial in Canada, Saudi Arabia, United States (NERv's Inline Device)

Recruiting
  • Anastomotic Leak
  • NERv's Inline Device
  • Cleveland, Ohio
  • +5 more
Jan 20, 2023

SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19 Trial (Bivalent BNT162b2 (original/Omicron

Not yet recruiting
  • SARS-CoV-2 Virus
  • +2 more
  • Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
  • +4 more
  • (no location specified)
Sep 14, 2022

B Acute Lymphoblastic Leukemia Trial (procedure, biological, drug, radiation)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • Biospecimen Collection
  • +19 more
  • (no location specified)
Nov 8, 2023

PH1, Primary Hyperoxaluria, RNAi Therapeutic Trial in Worldwide (Lumasiran)

Active, not recruiting
  • PH1
  • +4 more
  • Bordeaux, France
  • +8 more
Jan 13, 2023

Thrombocythemia, Essential Trial in San Antonio (IMG-7289)

Recruiting
  • Thrombocythemia, Essential
  • San Antonio, Texas
    Mays Cancer Center
Dec 14, 2021

Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas Trial in United States (AP-PA02, Placebo)

Active, not recruiting
  • Cystic Fibrosis
  • +4 more
  • AP-PA02
  • Placebo
  • Los Angeles, California
  • +19 more
Dec 20, 2022

HNSCC, Melanoma, Gynecologic Cancer Trial in Portland (DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2)

Recruiting
  • HNSCC
  • +5 more
  • DP CD8 TIL
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Jun 5, 2023

AML, MDS, ALL, Adult Trial in Hackensack, New York (SOC + TSC-100, SOC + TSC-101, Control)

Recruiting
  • AML
  • +2 more
  • SOC + TSC-100
  • +2 more
  • Hackensack, New Jersey
  • +1 more
Aug 11, 2022

Primary Hyperoxaluria, Primary Hyperoxaluria Type 2, End Stage Renal Disease Trial in Spain, United Kingdom, United States

Recruiting
  • Primary Hyperoxaluria
  • +2 more
  • Rochester, Minnesota
  • +4 more
Jul 7, 2021

PD-1 and Enhances Killing pH + Leukemia Stem Cells

Recruiting
  • Chronic Myeloid Leukemia
    • Guangzhou, Guangdong, China
      Department of Hematology,Nanfang Hospital, Southern Medical Univ
    Aug 4, 2021

    IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation Trial in Chicago (Ivosidenib, Enasidenib, Fedratinib)

    Recruiting
    • IDH Mutation
    • +4 more
    • Chicago, Illinois
      University of Chicago Medical Center
    Nov 12, 2021

    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein

    Recruiting
    • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +7 more
    • Blinatumomab
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 31, 2022

    High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

    Not yet recruiting
    • High Grade Ovarian Cancer
    • +2 more
    • (no location specified)
    Jul 11, 2022

    B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma Trial

    Not yet recruiting
    • B Acute Lymphoblastic Leukemia
    • +5 more
    • Biospecimen Collection
    • +4 more
    • (no location specified)
    Oct 28, 2022

    B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia Trial in Duarte (Cyclophosphamide, Cytarabine, Daunorubicin

    Recruiting
    • B Acute Lymphoblastic Leukemia
    • Ph-Like Acute Lymphoblastic Leukemia
    • Duarte, California
      City of Hope Medical Center
    Jul 26, 2022

    Atopic Dermatitis, Psoriasis, Asthma Trial in United Kingdom (EDP1867, Placebo)

    Completed
    • Atopic Dermatitis
    • +2 more
    • Manchester, Greater Manchester, United Kingdom
    • +6 more
    Oct 6, 2022